A large-scale meta-analysis of 32 phase 3 randomized controlled trials involving 43,618 adults with overweight or obesity demonstrates that GLP-1 receptor agonists and multi-hormone modulators produce clinically meaningful systolic blood pressure reductions averaging 5.2 mmHg after placebo adjustment. While 77% of this effect tracks with the observed 10.9% weight loss, the remaining variance points to direct mechanisms including renal natriuresis, vascular smooth-muscle relaxation, and attenuated sympathetic outflow. These findings align with and extend results from the SELECT trial (Lincoff et al., NEJM 2023; n=17,604), where semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease—an outcome only partially explained by the 9.4% average weight reduction. The unpublished European Congress on Obesity analysis, led by Marcel Muskiet at Leiden University Medical Center, correctly notes weight-independent contributions yet underplays how these same pathways intersect with the broader metabolic syndrome cluster. Chronic low-grade inflammation, endothelial dysfunction, and sodium retention form a self-reinforcing loop that GLP-1 therapies interrupt at multiple nodes, an insight supported by mechanistic reviews in Diabetes Care (2022) examining GLP-1 effects on renal sodium handling. The original Healthline coverage accurately reports the 0.34 mmHg drop per 1% weight lost but misses the public-health implication: integrating GLP-1 therapy into hypertension guidelines could shift treatment paradigms from reactive blood-pressure lowering to proactive metabolic reprogramming, particularly for the 59% of trial participants already hypertensive. Long-term durability, cost-effectiveness, and equitable access remain open questions requiring dedicated outcome trials.